Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
clinical trials
life sciences
national blog main
boston blog main
alnylam pharmaceuticals
boston
boston top stories
rna interference
archive
drugs
biotech
medical
patisiran
recalls
safety
alexion pharmaceuticals
aminolevulinic acid
deals
givosiran
hereditary transthyretin amyloidosis
national top stories
new york blog main
new york top stories
onpattro
roche
san francisco blog main
san francisco top stories
a2a pharmaceuticals
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
amyotrophic lateral sclerosis (als)
andrew fire
artificial intelligence
atea pharmaceuticals
What
drug
16
×
pharmaceuticals
16
×
medicine
fda
medication
new
alnylam
medicines
recall
announced
approved
data
recalled
rna
rnai
acella
ago
alternative
based
blood
consumers
cure
deal
disease
far
high
interference
making
market
ok
pharma
popular
potent
pressure
rare
roche
second
seek
speedy
thyroid
Language
unset
Current search:
pharmaceuticals
×
drug
×
@thenextweb.com
1 year ago
Icelandic startup bags €6M EU grant to fight drug-resistant infections
@slashgear.com
3 years ago
Popular thyroid drug recalled because the pills aren’t potent enough
@slashgear.com
3 years ago
High blood pressure drug recalled because labels were mixed up
@bgr.com
3 years ago
This groundbreaking new coronavirus cure is unlike any other drug we’ve seen so far
@slashgear.com
4 years ago
Popular thyroid drug recalled because it’s ‘super potent’ says FDA
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@slashgear.com
4 years ago
High blood pressure drug recall expands again over cancer risk
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@venturebeat.com
5 years ago
Consortium.AI wants to cure rare diseases using artificial intelligence
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@theverge.com
6 years ago
Cheaper alternative to EpiPen allergy shot approved by FDA
@extremetech.com
8 years ago
Drug company reneges on promise to reverse 5,400-percent price hike on Daraprim